(RTTNews) - U.S. biomarker diagnostics company Quanterix Corp. (QTRX) announced on Monday that it has appointed physician executive Yuri Fesko as Chief Medical Officer. Fesko will provide medical and clinical leadership across the company, as it prepares for the broader launch of its Lucent AD Complete Alzheimer's test and advances regulatory filings for its HD-X instrument. Fesko had previously served as Chief Medical Officer at Quest Diagnostics, overseeing medical affairs, clinical development and public health. On the Nasdaq, shares of Quanterix are currently losing 0.78 percent, changing hands at $2.5400 (RTTNews) - U.S. biomarker diagnostics company Quanterix Corp.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.